Citius Oncology Inc (Nasdaq: CTOR), a US-based specialty biopharmaceutical company, announced its financial results for the fiscal full year ended 30 September 2024 on Friday.
The company reported R&D expenses at USD4.9m for the full year ended 30 September 2024 compared to USD4.2m for the year-ended 30 September 2023.
The firm posted G&A expenses at USD8.1m for the full year ended 30 September 2024, compared to USD5.9m for the same period in 2023.
The company reported stock-based compensation expense at USD7.5m for the full year ended 30 September 2024, compared to USD2m for the full year ended 30 September, 2023.
The firm reported net loss at USD21.1m or USD0.31 per share for the full year ended 30 September 2024, compared to a net loss of USD12.7m or USD0.19 per share for the full year ended 30 September 2023.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis